Caribou Biosciences Inc. (CRBU)$2.10

Market Cap: 79.86 MCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Caribou Biosciences Inc. (CRBU).

HEALTHCARE

BIOTECHNOLOGY

DCF ready

Valuation

-0.6x

EV/FCF, N/A FCF yield

Quality

-121.2%

ROIC, -1006.8% FCF margin

Growth

-2.0%

5Y sales (revenue) CAGR

Balance sheet

0.0x

Debt/equity, 5.7x current ratio

Superinvestors

Top: Lee Ainslie (0.0%)

Strengths to research

Debt/equity looks manageable at 0.0x.

Watchouts

Free cash flow margin is negative at -1006.8%.
Five-year revenue trend is negative at -2.0%.

Annual data: 7 periods

Quarterly data: 24 periods

Stock snapshot: May 25, 2026

Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for CRBU.

Grade F

/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best


CRBU Target	Caribou Biosciences Inc.	$79.9M	-1.3x	-0.6x	-121.2%	-2.0%	-1006.8%	N/A	N/A	N/A
GUTS	Fractyl Health Inc	$79.8M	-0.5x	0.0x	-1490.3%	N/A	N/A	N/A	N/A	N/A
IVVD	Invivyd Inc.	$69.0M	-3.7x	2.7x	-21.7%	N/A	-109.1%	N/A	N/A	N/A
COYA	Coya Therapeutics Inc	$107.2M	-3.8x	-5.6x	-49.3%	N/A	-135.2%	N/A	N/A	N/A
GANX	Gain Therapeutics Inc.	$56.4M	-2.9x	-1.9x	-106.3%	N/A	N/A	N/A	N/A	N/A
CGEN	Compugen Ltd	$128.1M	7.4x	1.2x	34.4%	105.2%	43.1%	87.3%	-2.8x	N/A
PEPG	Pepgen Inc	$47.1M	-0.7x	0.2x	-60.8%	N/A	N/A	N/A	N/A	N/A
DMAC	DiaMedica Therapeutics Inc.	$171.4M	N/A	-5.4x	-58.4%	N/A	N/A	N/A	N/A	N/A
INBX	Inhibrx	$178.5M	-11.2x	-0.4x	-1752.2%	N/A	-9986.5%	N/A	N/A	N/A

Financial Charts

No financial data available for CRBU (annual).

1 superinvestors own CRBU

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership

Fund	Shares	Value	% Portfolio	QoQ Change
Lee Ainslie Maverick Capital	652,542	$1M	0.01%	0.0%